Product Name :
N-Ethyl-3, 3, 3-trifluoro-N-methylpropanamide-PEG2-Br
Description:
N-Ethyl-333-trifluoro-N-methylpropanamide-PEG2-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
CAS:
Molecular Weight:
336.15
Formula:
C10H17BrF3NO3
Chemical Name:
N-2-[2-(2-bromoethoxy)ethoxy]ethyl-3,3,3-trifluoro-N-methylpropanamide
Smiles :
CN(CCOCCOCCBr)C(=O)CC(F)(F)F
InChiKey:
IFJWNKDDGDBITI-UHFFFAOYSA-N
InChi :
InChI=1S/C10H17BrF3NO3/c1-15(9(16)8-10(12,13)14)3-5-18-7-6-17-4-2-11/h2-8H2,1H3
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
N-Ethyl-333-trifluoro-N-methylpropanamide-PEG2-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.|Product information|Molecular Weight: 336.15|Formula: C10H17BrF3NO3|Chemical Name: N-2-[2-(2-bromoethoxy)ethoxy]ethyl-3,3,3-trifluoro-N-methylpropanamide|Smiles: CN(CCOCCOCCBr)C(=O)CC(F)(F)F|InChiKey: IFJWNKDDGDBITI-UHFFFAOYSA-N|InChi: InChI=1S/C10H17BrF3NO3/c1-15(9(16)8-10(12,13)14)3-5-18-7-6-17-4-2-11/h2-8H2,1H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.SiRNA Negative Control web |Shelf Life: ≥12 months if stored properly.Norepinephrine Technical Information |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:32686510 |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.|References:|An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562Products are for research use only. Not for human use.|